Cultural advice

The Australian National University acknowledges, celebrates and pays our respects to the Ngunnawal and Ngambri people of the Canberra region and to all First Nations Australians on whose traditional lands we meet and work, and whose cultures are among the oldest continuing cultures in human history.

Aboriginal and Torres Strait Islander peoples are advised that ANU Library collections may include images, names, voices, and other representations of deceased persons.

Material in the collection may contain terms, language or views that reflect the period in which the item was created and may be considered inappropriate today.

Effectiveness of biologics in Australian patients with rheumatoid arthritis: a large observational study: REAL

dc.contributor.authorNicholls, Dave
dc.contributor.authorBarrett, Rina
dc.contributor.authorButton, Peter
dc.contributor.authorTruman, Matt
dc.contributor.authorBIRD, Paul
dc.contributor.authorRoberts, L
dc.contributor.authorTymms, Kathleen
dc.contributor.authorLittlejohn, Geoffrey
dc.contributor.authorGriffiths, Hedley
dc.date.accessioned2021-02-01T05:08:51Z
dc.date.issued2018
dc.date.updated2020-11-02T04:24:40Z
dc.description.abstractBackground: The comparative effectiveness of biologic treatment regimens in a real world Australian population is unknown. Aim: To assess the effectiveness of biological disease-modifying anti-rheumatic drugs (bDMARD) as monotherapy or in combination with methotrexate and/or other conventional DMARD (cDMARD) for the treatment of rheumatoid arthritis (RA). Methods: A retrospective, non-interventional study was conducted that investigated the use of bDMARD in adult patients with RA in routine clinical practice. Data were extracted from the Optimising Patient Outcomes in Australian Rheumatology – Quality Use of Medicines Initiative database. Real-world effectiveness was measured using the 28-joint disease activity score (DAS28) and clinical disease activity index (CDAI) by treatment group at baseline, weeks 12 and 24. Results: A total of 2970 patients was included with a median (min–max) age of 60.0 (19.0–94.0) years and median (min–max) duration of RA before first bDMARD treatment of 6.0 (0.2–58.3) years. A total of 1177 patients received more than one bDMARD during the analysis period of 1 January 1997 to 15 August 2015. Patients had 4922 treatment ‘episodes’ (defined as a cycle of continuous individual bDMARD prescribing in a single patient). Patients received a mean (SD) of 1.7 (1.0) episodes of treatment with median (min–max) treatment duration of 0.7 (0–11.8) years; median treatment duration was higher with the first treatment episode. bDMARD were most commonly initiated in combination with methotrexate (73.9% of episodes) and least commonly as monotherapy (9.9% of episodes). Median (min–max) baseline DAS28 decreased from 5.3 (0–8.7) with the first bDMARD to 3.7 (0–8.8) with the second. Median baseline CDAI similarly decreased. Conclusions: Patients tended to persist longer on their first bDMARD treatment. bDMARD as monotherapy or in combination appear to be accepted treatment strategies in the real worlden_AU
dc.format.mimetypeapplication/pdfen_AU
dc.identifier.issn1444-0903en_AU
dc.identifier.urihttp://hdl.handle.net/1885/220536
dc.language.isoen_AUen_AU
dc.publisherBlackwell Science Asiaen_AU
dc.rights© 2018 Royal Australasian College of Physiciansen_AU
dc.sourceInternal Medicine Journalen_AU
dc.source.urihttps://onlinelibrary.wiley.com/doi/full/10.1111/imj.14028en_AU
dc.subjectrheumatoid arthritisen_AU
dc.subjectpersistenceen_AU
dc.subjectbiologic DMARDen_AU
dc.subjectmonotherapyen_AU
dc.subjectOPAL-QUMIen_AU
dc.titleEffectiveness of biologics in Australian patients with rheumatoid arthritis: a large observational study: REALen_AU
dc.typeJournal articleen_AU
local.bibliographicCitation.issue10en_AU
local.bibliographicCitation.lastpage1192en_AU
local.bibliographicCitation.startpage1185en_AU
local.contributor.affiliationNicholls, Dave, Coast Joint Careen_AU
local.contributor.affiliationBarrett, Rina, Roche Products Pty Limiteden_AU
local.contributor.affiliationButton, Peter, Roche Products Pty Limiteden_AU
local.contributor.affiliationTruman, Matt, Roche Products Pty Limiteden_AU
local.contributor.affiliationBIRD, Paul, Combined Rheumatology Practiceen_AU
local.contributor.affiliationRoberts, L, Monash Universityen_AU
local.contributor.affiliationTymms, Kathleen, College of Health and Medicine, ANUen_AU
local.contributor.affiliationLittlejohn, Geoffrey, Monash Universityen_AU
local.contributor.affiliationGriffiths, Hedley, Barwon Rheumatology Serviceen_AU
local.contributor.authoruidTymms, Kathleen, u5095765en_AU
local.description.embargo2099-12-31
local.description.notesImported from ARIESen_AU
local.identifier.absfor110322 - Rheumatology and Arthritisen_AU
local.identifier.absseo920116 - Skeletal System and Disorders (incl. Arthritis)en_AU
local.identifier.ariespublicationu5234101xPUB288en_AU
local.identifier.citationvolume48en_AU
local.identifier.doi10.1111/imj.14028en_AU
local.publisher.urlhttps://onlinelibrary.wiley.com/doi/full/10.1111/imj.14028en_AU
local.type.statusPublished Versionen_AU

Downloads

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
01_Nicholls_Effectiveness_of_biologics_in_2018.pdf
Size:
1.78 MB
Format:
Adobe Portable Document Format